Skip to content
Dx

ICD-10-CM 2027 diagnosis code

Z16.13Resistance to carbapenem

✓ Billable / specificNot a principal dx

Z16.13 is a valid, billable ICD-10-CM code for resistance to carbapenem. It can be reported on claims for dates of service from October 1, 2026 – September 30, 2027.

Code last changed in FY2024 (effective October 1, 2023). Source: official FY2027 ICD-10-CM release from CDC/NCHS and CMS. Page updated September 29, 2026. About our data

About Z16.13

Z16.13 is the ICD-10-CM diagnosis code for resistance to carbapenem. It belongs to category Z16 (resistance to antimicrobial drugs), block Z16 (resistance to antimicrobial drugs) and chapter 21 (factors influencing health status and contact with health services). It is billable, so it can be reported on its own for dates of service from October 1, 2026 through September 30, 2027.

Within Z16.1 (resistance to beta lactam antibiotics), Z16.13 is specifically for resistance to carbapenem. Related codes cover resistance to unspecified beta lactam antibiotics (Z16.10), resistance to penicillins (Z16.11), extended spectrum beta lactamase (ESBL) resistance (Z16.12) and resistance to other specified beta lactam antibiotics (Z16.19).

Code first: the infection.

It is not a CC or MCC, so as a secondary diagnosis it doesn't change the MS-DRG severity level.

In MS-DRG v44.0, it is part of the grouping logic for DRG 867 (Other Infectious and Parasitic Diseases Diagnoses with MCC, relative weight 2.1859), DRG 868 (Other Infectious and Parasitic Diseases Diagnoses with CC, relative weight 1.0235) and DRG 869 (Other Infectious and Parasitic Diseases Diagnoses without CC/MCC, relative weight 0.6787), in MDC 18 (Infectious and Parasitic Diseases, Systemic or Unspecified Sites), as a principal or secondary diagnosis. The DRG a claim lands in depends on the principal diagnosis, procedures and any CC/MCC secondary diagnoses.

It is not acceptable as the principal diagnosis for an inpatient stay; it may be reported as a secondary diagnosis.

It was added in FY2024, effective October 1, 2023.

Notes that apply from higher levels

Instructions written at a parent level also apply to Z16.13.

› From Z16 Resistance to antimicrobial drugs
Note
  • The codes in this category are provided for use as additional codes to identify the resistance and non-responsiveness of a condition to antimicrobial drugs.
Excludes1
  • Methicillin resistant Staphylococcus aureus infection (A49.02)
  • Methicillin resistant Staphylococcus aureus pneumonia (J15.212)
  • Sepsis due to Methicillin resistant Staphylococcus aureus (A41.02)
Code first
  • the infection

Broader instructions also apply from Chapter 21: Factors influencing health status and contact with health services.

Alphabetic index entries

1 entries

Terms in the official ICD-10-CM index that lead to Z16.13.

MS-DRG v44.0 grouping

All DRGs →

Inpatient MS-DRGs this diagnosis can group to, as the principal or a secondary diagnosis, depending on the rest of the claim.

Code history

  1. 2016
  2. 2017
  3. 2018
  4. 2019
  5. 2020
  6. 2021
  7. 2022
  8. 2023
  9. 2024
  10. 2025
  11. 2026
  12. 2027
  • FY2024 (effective 10/1/2023): Added
  • No changes since FY2024.

Common questions about Z16.13

Is Z16.13 billable?

Yes. Z16.13 is a billable/specific ICD-10-CM code valid for FY2027 (October 1, 2026 – September 30, 2027).

Can Z16.13 be used as a principal diagnosis?

No. It is not acceptable as the principal diagnosis for an inpatient stay; it may be reported as a secondary diagnosis.

Is Z16.13 a CC or MCC?

No. Z16.13 is neither a CC nor an MCC under MS-DRG v44.0.

What DRG does Z16.13 group to?

Z16.13 is used in the MS-DRG v44.0 logic for MS-DRG 867 (Other Infectious and Parasitic Diseases Diagnoses with MCC), MS-DRG 868 (Other Infectious and Parasitic Diseases Diagnoses with CC) and MS-DRG 869 (Other Infectious and Parasitic Diseases Diagnoses without CC/MCC). Which one applies depends on whether it is the principal diagnosis and on the rest of the claim.